{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:33:40Z","timestamp":1789385620968,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1093\/annonc\/mdh280","type":"journal-article","created":{"date-parts":[[2004,6,17]],"date-time":"2004-06-17T19:14:50Z","timestamp":1087499690000},"page":"1109-1114","source":"Crossref","is-referenced-by-count":58,"title":["Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma"],"prefix":"10.1016","volume":"15","author":[{"given":"M.","family":"Aklilu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Markiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.J.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mahowald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.F.","family":"Gajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh280_bb0010","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.4049\/jimmunol.135.5.3623","article-title":"Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells","volume":"135","author":"Ettinghausen","year":"1985","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.4049\/jimmunol.135.2.1488","article-title":"Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues","volume":"135","author":"Ettinghausen","year":"1985","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"J Am Med Assoc"},{"key":"10.1093\/annonc\/mdh280_bb0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000012085","article-title":"The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group","volume":"58","author":"Keilholz","year":"2000","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdh280_bb0030","first-page":"194","article-title":"Interleukin-2 in the treatment of renal cancer","volume":"27","author":"Margolin","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh280_bb0035","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","article-title":"Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report","volume":"12","author":"Yang","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh280_bb0040","first-page":"67","article-title":"Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma","volume":"22","author":"Stadler","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdh280_bb0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4049\/jimmunol.121.1.359","article-title":"Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor","volume":"121","author":"Brodt","year":"1978","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0050","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/00007890-199306000-00027","article-title":"4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells","volume":"55","author":"Monach","year":"1993","journal-title":"Transplantation"},{"key":"10.1093\/annonc\/mdh280_bb0055","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm0598-627","article-title":"B cells inhibit induction of T cell-dependent tumor immunity","volume":"4","author":"Qin","year":"1998","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdh280_bb0060","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.4049\/jimmunol.159.10.4665","article-title":"Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic\/RAG(\u2212\/\u2212) mice","volume":"159","author":"Manning","year":"1997","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0065","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.4049\/jimmunol.163.8.4109","article-title":"Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1","volume":"163","author":"Fallarino","year":"1999","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0070","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh280_bb0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1093\/annonc\/mdh280_bb0080","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdh280_bb0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00002371-200205000-00010","article-title":"Flt-3 ligand and sequential FL\/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity","volume":"25","author":"Rini","year":"2002","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdh280_bb0090","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4049\/jimmunol.146.6.1750","article-title":"Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations","volume":"146","author":"Gajewski","year":"1991","journal-title":"J Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/PL00006672","article-title":"B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion","volume":"48","author":"Barbera-Guillem","year":"2000","journal-title":"Cancer Immunol Immunother"},{"key":"10.1093\/annonc\/mdh280_bb0100","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/intimm\/10.3.355","article-title":"Stach RM. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses","volume":"10","author":"Rowley","year":"1998","journal-title":"Int Immunol"},{"key":"10.1093\/annonc\/mdh280_bb0105","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1084\/jem.139.6.1473","article-title":"Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus","volume":"139","author":"Kirchner","year":"1974","journal-title":"J Exp Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/7\/1109\/678801\/mdh280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T21:36:31Z","timestamp":1682717791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341948037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S092375341948037X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh280","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]}}}